The Effect of Eight Weeks of Aerobic Exercise on the Plasma Levels of WISP-1 and WISP-2 in Diabetic and Healthy Rats

Subject Areas : Journal of Animal Biology

Mehdi Karimi ¹ (Department of Physical Education and Sport Sciences, Saghez Branch, Islamic Azad University, Saghez, Iran)
Saman Pashaei ² (Department of Physical Education and Sport Sciences, Saghez Branch, Islamic Azad University, Saghez, Iran)
Ayoub Saeidi ³ (Department of Physical Education and Sport Sciences, Faculty of Humanities and Social Sciences, University of Kurdistan, Sanandaj, Kurdistan, Iran)

Received: 2022-10-11 Accepted : 2023-12-01 Published : 2024-02-20

Keywords: Aerobic exercise, Diabetic rat, WISP-1, WISP-2,

Abstract :

Diabetes and related diseases are one of the leading causes of death in the world. The aim of this study was to evaluate the effect of eight weeks of moderate intensity aerobic exercise on plasma levels of WISP-1 and WISP-2 in streptozotocin-induced diabetic rats. Forty male Wistar rats were randomly divided into 4 groups: control, control + diabetes, training, training + diabetes after getting acquainted with the new environment and how to work on the treadmill. The training program for the 8-week training group was: 5 sessions per week of running on a rodent treadmill for 60 minutes at a speed of 25 meters per minute was equivalent to 50 to 60% Vo2max. Blood samples were taken from the subjects of all research groups 48 hours after the last training session and were used to analyze the indicators. One-way analysis of variance and Tukey's post hoc test were used for comparison between groups for data analysis. The results of one-way analysis of variance showed that there was a significant difference between the groups in relation to WISP2 and WISP-2 levels (P = 0.001). Conclusion: Based on the present findings, it can be stated that moderate intensity aerobic exercise can also be effective in modulating plasma levels of WISP-1 and WISP-2 in diabetes.

References:

1. Bahreini A., Fathi R. 2017. Comparing the Effect of Eight Weeks of Interval and Continuous Aerobic Training on Serum Levels of WISP1 and TNF-α in Overweight/0bese Girls. Journal of Sport and Biomotor Sciences, 10(18):1-12.


2. Brandt C., Pedersen B.K. 2010. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. BioMed Research International, 2010:520258.


3. Bugger H., Abel E.D. 2009. Rodent models of diabetic cardiomyopathy. Disease Models and Mechanisms, 2(9-10):454-66.


4. Chang J.S., Kim T.H., Kong I.D. 2020. Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors: A randomized controlled trial. Scientific Reports, 10(1):1-9.


5. Grünberg J.R., Hammarstedt A., Hedjazifar S., Smith U. 2014. The Novel Secreted Adipokine WNT1-Inducible-Signaling Pathway Protein2/WISP2 is a Mesenchymal Cell Activator of Canonical NT. Journal of Biological Chemistry. 2014:jbc.M113. 511964.


6. Grünberg J. 2015. WISP-2-A Novel Adipokine Related to Obesity and Insulin resistance. University of Gothenburg Press.


7. Grundy SM, Cleeman JI, Daniels SR, Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C. Jr, Spertus J.A., Costa F. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112(17):2735-2752.


8. Gustafson B., Hammarstedt A., Hedjazifar S., Smith U. 2013. Restricted adipogenesis in hypertrophic obesity: the role of WISP2, WNT, and BMP4. Diabetes, 62(9):2997-3004.


9. Hammarstedt A., Hedjazifar S., Jenndahl L., Gogg S., Grünberg J., Gustafson B., et al. 2013. WISP2 regulates preadipocyte commitment and PPARγ activation by BMP4. Proceedings of the National Academy of Sciences, 110(7):2563-2568.


10. Hörbelt T., Tacke C., Markova M., de Wiza D.H., Van de Velde F., Bekaert M., et al. 2018. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia, 61(9):2054-65.


11. Klimontov V.V., Bulumbaeva D.M., Fazullina O.N., Lykov A.P., Bgatova N.P., Orlov N.B., Konenkov V.I., Pfeiffer A.F.H., Pivovarova-Ramich O., Rudovich N. 2020. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. Journal of Cell Communication and Signaling, 14(1):101-109.


12. Kyu H.H., Bachman V.F., Alexander L.T., Mumford J.E., Afshin A., Estep K., Veerman J.L., Delwiche K., Iannarone M.L., Moyer M.L., Cercy K., Vos T., Murray C.J., Forouzanfar M.H. 2016. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ, 354:i3857.


13. Maiese K., Chong Z.Z., Shang Y.C., Wang S. 2012. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opinion on Therapeutic Targets, 16(12):1203-1214.


14. Maury E., Brichard S. 2010. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Molecular and Cellular Endocrinology, 314(1):1-16.


15. Mirr M., Owecki M. 2021. An Update to the WISP-1/CCN4 role in obesity, insulin resistance and diabetes. Medicina, 57(2):100.


16. Murahovschi V., Pivovarova O., Ilkavets I., Dmitrieva R.M., Döcke S, Keyhani-Nejad F., Gögebakan Ö., Osterhoff M., Kemper M., Hornemann S., Markova M., Klöting N., Stockmann M., Weickert M.O., Lamounier-Zepter V., Neuhaus P., Konradi A., Dooley S., von Loeffelholz C., Blüher M., Pfeiffer A.F., Rudovich N. 2014. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes, 2014:DB-140444.


17. Murahovschi V., Pivovarova O., Ilkavets I., Dmitrieva R.M., Döcke S, Keyhani-Nejad F., Gögebakan Ö., Osterhoff M., Kemper M., Hornemann S., Markova M., Klöting N., Stockmann M., Weickert M.O., Lamounier-Zepter V., Neuhaus P., Konradi A., Dooley S., von Loeffelholz C., Blüher M., Pfeiffer A.F., Rudovich N. 2015. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes, 64(3):856-66.


18. Pakradouni J., Le Goff W., Calmel C., Antoine B., Villard E., Frisdal E., Abifadel M., Tordjman J., Poitou C., Bonnefont-Rousselot D., Bittar R., Bruckert E., Clément K., Fève B., Martinerie C., Guérin M. 2013. Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders. PLoS One, 8(6):e66788.


19. Peake J.M., Suzuki K., Coombes J.S. 2007. The influence of antioxidant supplementation on markers of inflammation and the relationship to oxidative stress after exercise. The Journal of Nutritional Biochemistry, 18(6):357-371.


20. Roberts I., Kwan I., Evans P., Haig S. 2002. Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. British Medical Journal, 324(7335):474.


21. Tacke C., Aleksandrova K., Rehfeldt M., Murahovschi V., Markova M., Kemper M., Hornemann S., Kaiser U., Honig C., Gerbracht C., Kabisch S., Hörbelt T., Ouwens D.M., Weickert M.O., Boeing H., Pfeiffer A.F.H., Pivovarova O., Rudovich N. 2018. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. Journal of Cell Communication and Signaling,12(3):539-548.


22. Talebi-Garakani E., Safarzade A. 2013. Resistance training decreases serum inflammatory markers in diabetic rats. Endocrine, 43(3):564-70.